Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug;158(2):354-360.
doi: 10.1016/j.ygyno.2020.05.013. Epub 2020 May 24.

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

Julian C Schink  1 , Virginia Filiaci  2 , Helen Q Huang  3 , John Tidy  4 , Matthew Winter  5 , Jeanne Carter  6 , Nancy Anderson  7 , Katherine Moxley  8 , Akira Yabuno  9 , Sarah E Taylor  10 , Christina Kushnir  11 , Neil Horowitz  12 , David S Miller  13
Affiliations
Clinical Trial

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

Julian C Schink et al. Gynecol Oncol. 2020 Aug.

Abstract

Objectives: Methotrexate and actinomycin-D are both effective first-line drugs for low-risk (WHO score 0-6) Gestational Trophoblastic Neoplasia (GTN) with considerable debate about which is more effective, less toxic, and better tolerated. The primary trial objective was to test if treatment with multi-day methotrexate (MTX) was inferior to pulse actinomycin-D (ACT-D). Secondary objectives included evaluation of severity and frequency of adverse events, and impact on quality of life (QOL).

Methods: This was a prospective international cooperative group randomized phase III two arm non-inferiority study (Clinical Trials Identifier: (NCT01535053). The control arm was ACT-D; the experimental arm was multi-day MTX regimen (institutional preference of 5 or 8 day). Outcome measures included complete response rate, recurrence rate, toxicity, and QOL as measured by FACT-G and FACIT supplemental items.

Results: The complete response rates for multi-day methotrexate and pulse actinomycin-D were 88% (23/26 patients) and 79% (22/28 patients) (p = NS) respectively, there were two recurrences in each arm, and 100% of patients survived. Significant toxicity was minimal, but mouth sores (mucositis), and eye pain were significantly more common in the MTX arm (p = 0.001 and 0.01 respectively). Quality of life showed no significant difference in overall quality of life, body image, sexual function, or treatment related side effects. The study was closed for low accrual rate (target 384, actual accrual 57), precluding statistical analysis of the primary objective.

Conclusions: The complete response rate for multi-day methotrexate was higher than actinomycin-D, but did not reach statistical significance. The multi-day MTX regimens were associated with significantly more mucositis and were significantly less convenient.

Keywords: Actinomycin-D; GOG; Gestational trophoblastic neoplasia; Multi-day methotrexate; NRG.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Dr. Julian Schink, Dr. Jeanne Carter, Dr. Matthew Winter, Dr. Nancy Anderson, Dr. Katherine Moxley, Dr. Akira Yabucoa, Dr. Sarah Taylor, Dr. Christina Kushnir, Dr. Neil Horowitz and Ms. Helen Huang have nothing to disclose. Dr. Virginia Filiaci reports grants from NIH, during the conduct of the study; grants from GOG Foundation, Inc., from null, outside the submitted work. Dr. Tidy reports personal fees from Zilico Ltd., outside of the submitted work. Dr. David Miller reports personal fees received as consultant for Tesaro, Eisai, Incyte, Karyopharm and Genentech. Dr. Miller also reports money was paid to his institution by Merck and grants received from nVision Medical, Advenchen, Forty Seven, Merck and Syros

Figures

Fig. 1.
Fig. 1.
Study schema for NRG/GOG 275.
Fig. 2.
Fig. 2.
Cumulative accrual.
Fig. 3.
Fig. 3.
Consort diagram.
See this image and copyright information in PMC

References

    1. Seckl MJ, Sebire NJ, Berkowitz RS, Gestational trophoblastic disease, Lancet 376 (2010) 717–729. - PubMed
    1. Berkowitz RS, Goldstein DP, Current management of gestational trophoblastic diseases, Gynecol. Oncol 112 (2009) 654–662. - PubMed
    1. Lurain JR, Classification and management of gestational trophoblastic neoplasia, Am. J. Obstet. Gynecol 204 (2011) 11–18. - PubMed
    1. Lybol C, Sweep FC, Harvey R, et al. , Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia, Gynecol. Oncol 125 (3) (2012) 576–579. - PubMed
    1. Osborne RJ, Filiaci G, Schink JC, et al. , A phase III trial of weekly methotrexate or pulsed dactinomycin for low risk gestational trophoblastic neoplasia: a Gynecologic Oncolgy Group study, J. Clin. Oncol 19 (2011) 825–831. - PMC - PubMed

Publication types

MeSH terms

Associated data